About Blue Rock Therapeutics
Blue Rock Therapeutics is a company based in Boston (United States) founded in 2016 was acquired by Leaps by Bayer in August 2019. Blue Rock Therapeutics has raised $225 million across 1 funding round from investors including Versant Ventures and Leaps by Bayer. The company has 138 employees as of December 31, 2022. Blue Rock Therapeutics offers products and services including bemdaneprocel and OpCT-001. Blue Rock Therapeutics operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Boston, United States
- Employees 138 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bluerock Therapeutics Lp
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$225 M (USD)
in 1 rounds
-
Latest Funding Round
$225 M (USD), Series A
Dec 12, 2016
-
Investors
Versant Ventures
& 1 more
-
Employee Count
138
as on Dec 31, 2022
-
Acquired by
Leaps by Bayer
(Aug 08, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Blue Rock Therapeutics
Blue Rock Therapeutics offers a comprehensive portfolio of products and services, including bemdaneprocel and OpCT-001.
Investigational therapy for treating Parkinson's disease in clinical trials.
Therapy for primary photoreceptor diseases through iPSC-derived cells.
People of Blue Rock Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
46 people
Software Development Team
43 people
Product Management Team
29 people
Senior Team
25 people
Scientist Team
9 people
Principal Team
9 people
Human Resources and Administration
7 people
Legal and Compliance
6 people
Unlock access to complete
Funding Insights of Blue Rock Therapeutics
Blue Rock Therapeutics has successfully raised a total of $225M through 1 strategic funding round. The most recent funding activity was a Series A round of $225 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Blue Rock Therapeutics
Blue Rock Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Versant Ventures and Leaps by Bayer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences sector
|
Locked | Locked | Locked |
Investor details for Blue Rock Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Blue Rock Therapeutics
Investment portfolio details for Blue Rock Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Blue Rock Therapeutics
Detailed financials for Blue Rock Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Blue Rock Therapeutics Comparisons
Peer comparison for Blue Rock Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Blue Rock Therapeutics
Blue Rock Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Detailed competitors of Blue Rock Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Blue Rock Therapeutics
Complete news archive for Blue Rock Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blue Rock Therapeutics
Blue Rock Therapeutics was founded in 2016.
Blue Rock Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Blue Rock Therapeutics is a funded company, having raised a total of $225M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Blue Rock Therapeutics is 138.
Blue Rock Therapeutics was founded in 2016 and is based in Boston, United States. Operations center on the biotechnology sector, where stem cell therapeutics are developed to address cardiovascular and neurological conditions. The lead program targets heart muscle regeneration for patients recovering from heart attacks or managing chronic heart failure. Additional efforts extend to broader neurological applications through stem cell-based treatments.
Blue Rock Therapeutics's top competitors include Merck, Roivant Sciences and AbbVie.
Blue Rock Therapeutics offers bemdaneprocel and OpCT-001.
Blue Rock Therapeutics has 2 investors. Key investors include Versant Ventures, and Leaps by Bayer.